远大医药(00512.HK)获授大中华地区乾眼症产品授权
远大医药(00512.HK)公布,近日与全福生技订立授权协议,公司将获得全福生技开发的全球首创治疗乾眼症的产品BRM421及相关技术的中国内地、香港及澳门地区之开发及商业化权利,公司并与全福生技订立股份认购协议,公司将认购全福生技的少部分股份,并将有权争取委任一个董事席次。
根据授权协议的约定,自订立授权协议日起,公司将获得BRM421於大中华地区的二十年独家开发及商业化权利,并进行产品技术转移,实现产品本地化生产。公司将根据开发进度及销售情况分阶段向全福生技支付授权首付款及里程碑款项,并根据BRM421的销售金额年度净额支付若干比例的权利金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.